InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Browse the detailed record of transactions filed by Orwin John A, Chairman & CEO. Officer active across 3 companies, notably Travere Therapeutics, Inc.. In total, 8 disclosures have been published. The latest transaction was filed on 13 May 2022 — Attribution. Regulator: SEC (Form 4). All data is openly available.
Declarations8 total
01,503 shares0
Common Stock
SEC:0000899243-22-018465:0·
03,000 shares0
Common Stock
SEC:0001209191-22-028699:0·
0115,400 shares0
Class A Common Stock
SEC:0001209191-21-055809·
0115,400 shares0
Class A Common Stock
SEC:0001209191-21-055809:0·
03,000 shares0
Common Stock
SEC:0001209191-21-033847·
01,402 shares0
Common Stock
SEC:0001203311-21-000032·
03,000 shares0
Common Stock
SEC:0001209191-21-033847:0·
01,402 shares0
Common Stock
SEC:0001203311-21-000032:0·
8 of 8 declarations
About Orwin John A
John A. Orwin is the President & CEO of Travere Therapeutics, Inc., Seagen Inc., and Atreca, Inc. He leads these companies with a strategic vision, overseeing operations and growth initiatives. John is responsible for implementing corporate strategies and managing stakeholder relationships. His experience in the biopharmaceutical sector is a valuable asset for the leadership of these organizations.
